Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : InterMune (nasdaq)ITMN -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (122)	8/14/2001 9:05:11 AM
From: rkrw	Read Replies (1) \| Respond to of 508

First hints of a second generation actimmune..... Tuesday August 14, 7:01 am Eastern Time Press Release SOURCE: InterMune, Inc. InterMune Announces Executive Appointments BRISBANE, Calif., Aug. 14 /PRNewswire/ -- InterMune, Inc. (Nasdaq: ITMN - news) today announced the appointment of Vida Shafiee to the position of Vice President of International Business Operations and Gary C. Visor, Ph.D. to the position of Vice President of Process and Technical Operations. Each appointee brings to InterMune more than eighteen years of experience in the life-science industry. ``Vida's broad knowledge of international business operations will be invaluable as InterMune commercializes its products worldwide,'' stated W. Scott Harkonen, M.D., President and CEO of InterMune. ``Vida will lead our international efforts through the formation of strategic partnerships with key distributors and by obtaining additional regulatory approvals abroad.'' *******``Gary brings with him exceptional expertise in the development of second-generation pegylated proteins,'' stated Dr. Harkonen. ``He will play a key role in designing and implementing InterMune's program to develop second-generation interferon products. We recognize the tremendous therapeutic potential of both Actimmune® and Infergen® and plan to bring second-generation products with improved efficacy and delivery to market.''******** Ms. Shafiee joins InterMune after seven years with Johnson & Johnson and four years with Baxter, Inc. While with Johnson and Johnson, Ms. Shafiee served as a Marketing Director focused on sales and marketing strategy, distributor management, and business development in international markets. Ms. Shafiee has launched and obtained regulatory approvals in global markets for multiple products. She also spent several years in various sales and marketing positions at Amersham Corporation with an emphasis on oncology. Ms. Shafiee holds a B.S. (Medical Technology) from the University of Utah. Dr. Visor joins InterMune after six years with Roche Biosciences and three years with Gilead Sciences. Most recently, Dr. Visor served as Director of Pharmaceutical Chemistry and Product Development/Preclinical Sciences at Roche. In this capacity he was instrumental in the discovery and development of several new chemical entities (NCEs), as well as new protein and peptide delivery technologies. While with Gilead, Dr. Visor served as Director of Formulation and Process Development where he was responsible for physicochemical characterization and dosage form design of antiviral therapeutics. He holds a Ph.D. (Medicinal Chemistry/Pharmaceutical Sciences) and received his B.S. (Chemistry) from the University of Florida.